



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Dated: 14/08/2018

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting for the FY 2018-19 held on Tuesday, 14th August 2018 with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on **Tuesday, 14th August 2018 at 5:00 p.m. and Concluded at 7.15 p.m.** at the Corporate Office of the Company at Sandu Nagar, D K Sandu Marg, Chembur, Mumbai inter alia, discussed the following business:-

1. It has approved Unaudited Financial Results for the Quarter ended 30th June 2018 along with Limited Review Report.
2. It has considered Re-appointment of Shri. Dilip Salgaocar (DIN:00044240) as the Independent Director with effect from 01st April 2019 after approval of the Shareholders in forthcoming Annual General Meeting.
3. It has considered Re-appointment of Dr Shri. Krishna Deshpande (DIN:06557518) as the Independent Director with effect from 01st April 2019 after approval of the Shareholders in forthcoming Annual General Meeting.
4. It has considered Re-appointment of Dr Madan Kapre (DIN:03113515) as the Independent Director with effect from 01st April 2019 after approval of the Shareholders in forthcoming Annual General Meeting.
5. It has considered Re-appointment of Shri. K Vinay Kumar (DIN:02322747) as the Independent Director with effect from 01st April 2019 after approval of the Shareholders in forthcoming Annual General Meeting.

You are requested to kindly take the same on record.



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Thanking You

Yours Faithfully

For Sandu Pharmaceuticals Limited



Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



Sandu Pharmaceuticals Ltd					
STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/06/18					
(Rs in Lakhs)					
Particulars	Qtr Ending June 2018	Qtr Ending March 2018	Qtr Ending June 2017	Year Ended March 2018 Audited	
I	Revenue From Operations	1110.86	1222.71	677.49	4915.99
II	Other Income	19.40	8.4	4.93	12.18
III	Total Income (I+II)	1130.26	1231.11	682.42	4928.17
IV	EXPENSES				
	Cost of materials consumed	167.49	258.45	188.59	741.93
	Purchases of Stock-in-Trade	583.09	575.01	319.16	2188.82
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-200.47	-88.54	-166.28	-91.38
	Excise duty on sale of goods				14.40
	Employee benefits expense	172.93	197.67	133.31	593.64
	Finance costs	25.42	28.2	30.70	123.10
	Depreciation and amortization expense	15.78	23.75	11.48	60.24
	Other expenses	330.55	196.21	239.10	1221.90
	Total expenses (IV)	1094.79	1190.75	736.06	4862.65
V	Profit/(loss) before exceptional items and tax (-IV)	35.47	40.36	-53.64	75.52
VI	Exceptional Items			0	
VII	Profit/(loss) before tax (V-VI)	35.47	40.36	-53.64	75.52
VIII	Tax expense:				
	(1) Current tax	9.13	10.39	0	19.78
	(2) Deferred tax	-6.11		0	-0.41
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	32.45	29.97	-53.64	56.15
X	Profit/(loss) for the period (IX+XII)	32.45	29.97	-53.64	56.15
XI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-1.63	-8.79	0.62	13.44
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-0.16		0	2.12
	B (i) Items that will be reclassified to profit or loss	0		0	
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XII	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	30.66	21.18	-53.02	67.47
XIII	Reserves Excluding Revaluation Reserve as per Balance sheet				1146.95
XIV	Paid Up Equity Capital (Face Value of Rs 10/- Per share)	708.10	708.10	708.10	708.10
XVI	Earnings per equity share (for continuing operation):				
	(1) Basic	0.46	0.42	-1.02	0.79
	(2) Diluted				

Mumbai
Date :-14.08.2018



For Sandu Pharmaceuticals Ltd

Managing Director

Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, Fax: +91 832 2407008, E-mail: sandupharma@sandu.in

CIN:L24233GA1985PLC001587

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14th August, 2018. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the years ended March 31, and the published year to date figures up to the end of the third quarter of the relevant financials years.
3. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly , as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
4. On April 1, 2018 the Company has adopted Ind As 115 using the cumulative effect method. Accordingly the comparative information is not restated in the audited/unaudited results for the quarter ended 31st March 2018, 30th June 2017 and year ended 31st March 2018. The adoption of the standard did not have any material impact to the financial results of the Company.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.

Date: - 14 /08/2018



For Sandu Pharmaceuticals Ltd


Managing Director



Dileep & Prithvi

CHARTERED ACCOUNTANTS

"LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER


ENDED ON 30TH JUNE, 2018

To,
**The Board of Directors,
Sandu Pharmaceuticals Limited,**
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sandu Pharmaceuticals Limited ("the Company") for the quarter ended June 30, 2018, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the company. Our responsibility is to issue a report on these standalone financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number : 122290W


Dileepkumar Shah
(Partner)
Membership Number : 046848



Place: Mumbai
Date: 14th August, 2018